Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Smartphone-Based Readerless System Measures Blood Glucose for Early Detection of Prediabetes

By LabMedica International staff writers
Posted on 03 Apr 2023

Prediabetes is characterized by high blood sugar levels that may progress to type 2 diabetes. More...

Fortunately, this condition can be reversed with lifestyle changes such as a healthier diet and exercise, if detected early. However, many individuals with prediabetes are unaware of their condition, which puts them at greater risk of developing diabetes and complications such as heart disease, kidney failure, and vision loss. Screening for prediabetes typically involves laboratory testing at a healthcare facility or using a portable glucometer for at-home testing. Unfortunately, access and cost may limit widespread screening. Now, researchers have discovered an optimal approach to enhance early detection of prediabetes.

Researchers at the University of Washington (Seattle, WA, USA) have developed GlucoScreen, which takes advantage of the capacitive touch sensing abilities of smartphones to measure blood glucose levels without the need for a separate reader. This approach will help reduce the cost and increase accessibility of glucose testing, particularly for large-scale one-time screenings. GlucoScreen test strips measure the electrochemical reaction created by mixing blood and enzymes as an amplitude along a curve at a rate of five times per second. The strip then transmits this curve data to the phone encoded as a series of touches at variable speeds using pulse width modulation. “Pulse width” refers to the distance between peaks in the signal - in this case, the length between taps. Each pulse width represents a value on the curve, with a greater distance between taps indicating a higher amplitude of the electrochemical reaction on the strip.

The new GlucoScreen system has several advantages over traditional glucose testing methods. By leveraging the capacitive touch sensing capabilities of smartphones, it eliminates the need for a separate reader, making glucose testing more accessible and cost-effective for one-time screening of a large population. Additionally, the system does not require complicated electronic components, reducing the cost of manufacturing and power consumption compared to conventional communication methods like Bluetooth and Wi-Fi. The test strip is designed with photodiodes, which draw power from the phone's flash, eliminating the need for batteries or a USB connection. The GlucoScreen app walks users through the testing process, and after the data is transmitted from the strip to the phone, the app uses machine learning to analyze the data and calculate a blood glucose reading.

The researchers conducted both in vitro and clinical testing to evaluate their approach. In the clinical study, they enrolled 75 consenting patients who were scheduled to undergo a laboratory blood glucose test. The performance of GlucoScreen was compared against that of a conventional strip and glucometer, with the laboratory test serving as the ground truth. While additional testing is required, the preliminary results suggest that GlucoScreen's accuracy is comparable to that of a glucometer. Of significance, the system was found to be accurate at the critical threshold between a normal blood glucose level of 99 mg/dL or below and prediabetes, which is defined as a blood glucose level between 100 and 125 mg/dL. The researchers believe that GlucoScreen's performance will improve with further inputs.

“In conventional screening, a person applies a drop of blood to a test strip, where the blood reacts chemically with the enzymes on the strip. A glucometer is used to analyze that reaction and deliver a blood glucose reading,” explained lead author Anandghan Waghmare, a Ph.D. student in the Allen School’s UbiComp Lab. “We took the same test strip and added inexpensive circuitry that communicates data generated by that reaction to any smartphone through simulated tapping on the screen. GlucoScreen then processes the data and displays the result right on the phone, alerting the person if they are at risk so they know to follow up with their physician.”

“Because we use the built-in capacitive touch screen that’s present in every smartphone, our solution can be easily adapted for widespread use. Additionally, our approach does not require low-level access to the capacitive touch data, so you don’t have to access the operating system to make GlucoScreen work.” explained co-author Jason Hoffman, a Ph.D. student in the Allen School. “We’ve designed it to be ‘plug and play.’ You don’t need to root the phone — in fact, you don’t need to do anything with the phone, other than install the app. Whatever model you have, it will work off the shelf.”

“One of the barriers I see in my clinical practice is that many patients can’t afford to test themselves, as glucometers and their test strips are too expensive. And, it’s usually the people who most need their glucose tested who face the biggest barriers,” said Thompson, a family physician and professor in the UW Department of Family Medicine and Department of Global Health. “Given how many of my patients use smartphones now, a system like GlucoScreen could really transform our ability to screen and monitor people with prediabetes and even diabetes.”

Related Links:
University of Washington


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Electrolyte Analyzer
BKE-B
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: GRAIL’s Galleri test uses machine learning to analyze cfDNA patterns for cancer signals and predict their likely location to guide further evaluation.

Multi-Cancer Blood Test Expands Detection to Cancers Lacking Routine Screening Options

Many lethal cancers lack routine screening and are often diagnosed only after symptoms emerge, limiting curative options. Standard programs in the United States cover a small subset of malignancies, leaving... Read more

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.